Searched over 200M research papers for "brain ischemia"
10 papers analyzed
These studies suggest that brain ischemia involves cellular acidosis, oxidative stress, and abnormal ion homeostasis, with potential therapeutic strategies including receptor antagonism, anti-inflammatory therapies, and neurorestoration techniques.
20 papers analyzed
Brain ischemia occurs due to a critical reduction in cerebral blood flow, leading to irreversible brain damage. The brain's high metabolic rate and dependence on glucose make it particularly vulnerable to ischemic conditions. Cellular acidosis and biochemical disturbances, initiated by abnormal intracellular ion homeostasis, play crucial roles in determining the survival of nerve cells during ischemia. The brain's intrinsic cell-cell and intracellular signaling mechanisms, which are normally responsible for information processing, become harmful under ischemic conditions, hastening energy failure and enhancing pathways underlying ischemic cell death.
Ischemia triggers a cascade of events, including a massive increase in extracellular glutamate, activation of resident immune cells like microglia, and production of inflammatory mediators. Protracted neuroinflammation is a predominant mechanism of secondary brain injury progression. Extracellular ATP and adenosine concentrations increase dramatically during ischemia, stimulating P2 and P1 receptors, respectively. While adenosine A1 receptors have neuroprotective effects, A2A receptor antagonists reduce excitotoxicity and control neuroinflammation, offering potential therapeutic benefits. Conversely, P2X7 receptor antagonism may attenuate brain damage by reducing intracellular Ca2+ loading and glutamate release.
Brain ischemia initiates the generation of nitrogen and oxygen free radicals, which mediate much of the damage following transient ischemia. Nitric oxide synthases (NOS) play a significant role, with NOS1 and NOS2 activities being broadly deleterious, while NOS3 activity in blood vessels improves blood flow. The production of superoxide and peroxynitrite further exacerbates cellular damage by modifying macromolecules and inducing apoptotic and necrotic pathways. Over-activation of poly(ADP-ribose) polymerase (PARP) due to DNA damage depletes NAD+, contributing significantly to brain damage.
Brain ischemia affects individuals across all age groups, from neonates to the elderly. Preclinical rodent models have shown that the timing of ischemic injury during different developmental stages results in varying neuronal injury and functional outcomes. Factors such as excitation/inhibition balance, oxidative stress, inflammatory responses, blood-brain barrier integrity, and white matter injury differ significantly between developmental ages and adults. Translational strategies focusing on neurorestoration and neural repair are being explored to improve outcomes after ischemic brain injury.
Cerebral ischemia triggers complex metabolic and cellular pathologies, leading to neuronal cell death and cerebral infarction. Metabolome-based techniques have been employed to analyze metabolic changes and identify potential biomarkers of ischemic stroke. These techniques provide insights into the cellular pathologic status and contribute to the development of new diagnostic and therapeutic approaches.
Diabetes exacerbates brain ischemia by causing macroangiopathies, increasing the severity of ischemia, and raising stroke mortality. The vascular lesions caused by diabetes include cardiac-origin brain embolism, atherosclerosis of large extracranial and intracranial arteries, and degenerative abnormalities within penetrating artery branches. These conditions predominantly result in deep subcortical brain infarcts.
Cerebral ischemia is accompanied by a marked inflammatory reaction, initiated by the expression of cytokines, adhesion molecules, and other inflammatory mediators. Interventions aimed at attenuating inflammation, such as blocking inducible nitric oxide synthase and cyclo-oxygenase-2, have shown promise in reducing ischemic damage. Although some clinical trials have not shown benefit, ongoing research continues to explore the efficacy of anti-inflammatory therapies in treating cerebral ischemia.
Transient ischemic brain injury can lead to massive neuronal death and progressive atrophy, sharing commonalities with neurodegeneration in Alzheimer's disease. Post-ischemic brain injury is associated with the deposition of amyloid and tau proteins, and dysregulation of Alzheimer's disease-associated genes. This suggests that brain ischemia may play a role in the development of Alzheimer's disease, providing a model for understanding its mechanisms.
Brain ischemia is a complex condition characterized by a cascade of biochemical, metabolic, and inflammatory events leading to significant neuronal damage. Understanding the underlying mechanisms, including purinergic signaling, oxidative stress, and the impact of comorbid conditions like diabetes, is crucial for developing effective therapeutic strategies. Ongoing research continues to explore novel approaches to mitigate the effects of ischemia and improve outcomes for affected individuals.
Most relevant research papers on this topic